RxDoctor Payments Data

Michael May, MD

Family Medicine · Fayetteville, ARNPI 1265939342

Payments from drug & device makers

$2,342in general payments, 2019–2025

Across 135 payments — averaging $17.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$531
  • Novo Nordisk$352
  • Pfizer$252
  • GSK$238
  • Amgen$184
  • Lilly USA, LLC$135
  • plus $651 from 17 others

What the payments were for

  • Food & beverage$2,342100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,342 in reported general payments places this provider in the 75th percentile of 1,347 family medicine providers in Arkansas.

See all family medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$79,212
Medicare patients
159
Services billed
3,347

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban63$50,016
OzempicSemaglutide16$16,742
Soliqua 100-33Insulin Glargine/Lixisenatide14$12,268
EntrestoSacubitril/Valsartan15$12,002
JardianceEmpagliflozin13$6,978
Rosuvastatin Calcium240$2,256
Insulin Lispro Kwikpen U-100Insulin Lispro12$1,811
Omeprazole157$1,722
Duloxetine Hcl106$1,410
Gabapentin103$1,343
Atorvastatin Calcium160$1,156
Levothyroxine Sodium133$1,065
SynthroidLevothyroxine Sodium21$1,019
Albuterol Sulfate HfaAlbuterol Sulfate48$923
Bupropion XlBupropion Hcl46$882

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$252$50,01663 claims
Novo NordiskOzempic$352$16,74216 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$28$12,26814 claims
Boehringer IngelheimJardiance$44$6,97813 claims
AbbVieSynthroid$531$1,01921 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,347 family medicine providers in Arkansas.

Other family medicine in Fayetteville

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →